AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
AVITA Medical, Inc.NASDAQ: RCEL
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -55.1%
Net margin was -55.1% in Q1 FY2026, up 19.7 pp from a year earlier. On a trailing-twelve-month basis it was -62.7%, up 16.9 pp year over year. Over 3 fiscal years it widened by 9.6 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 5 analysts of -28.2% for the fiscal year ending Dec 2026, up from -67.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -55.1%+10.8 pp QoQ
- Last fiscal yearDec 2025
- -67.8%+28.4 pp YoY
- LTMMar 2026
- -62.7%+16.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.7 pp | +9.2 pp | -10.5 pp |
| 1 year | +28.4 pp | +39.7 pp | +11.2 pp |
| 3 years | +9.6 pp | +68.0 pp | +58.4 pp |
| 5 years | +88.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -67.8%
- Year-over-year change
- +28.4pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -67.8% | +28.4pp |
| FY2024 | 2024-12-31 | -96.3% | -25.7pp |
| FY2023 | 2023-12-31 | -70.6% | +6.9pp |
| FY2022 | 2022-12-31 | -77.5% | -1.3pp |
| FY2021 | 2021-12-31 | -76.1% | — |
Net Margin vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 net margin of -62.7% is the 4th highest of the 8 companies compared; the peer median is -226.9%.
- Its year-over-year change of +16.9 pp is the 5th highest of 8, against a peer median of +26.0 pp.
- Over three fiscal years its change of +9.6 pp compares with a peer median of +811.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 6.4% | -1.8 pp | -4.8 pp | |
| LTM Mar 2026 | 1.5% | +11.3 pp | +18.4 pp | |
| LTM Mar 2026 | -16.4% | +26.0 pp | +30.9 pp | |
| LTM Mar 2026 | -62.7% | +16.9 pp | +9.6 pp | |
| LTM Mar 2026 | -226.9% | +116.5 pp | +811.4 pp | |
| LTM Mar 2026 | -339.3% | +4217.8 pp | +3364.5 pp | |
| LTM Mar 2026 | -876.7% | +604.8 pp | +13666.8 pp | |
| LTM Mar 2026 | -4987.4% | -3454.4 pp | +10754.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding RCEL) | -226.9% | +26.0 pp | +811.4 pp | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.